| Description | CAIX Inhibitor S4 (S4) is an effective inhibitor of carbonic anhydrase IX/XII with a Ki of 7 nM and 2 nM, respectively. The Kis for CA II and CA I are 546 and 5600 nM. |
| In vitro | CAIX Inhibitor S4 (33 μM; 15-60 min) delays the cell spreading of MDA-MB-231 cells in anoxia but essentially not in normoxia. CAIX Inhibitor S4 (1, 10, 100 μM; 24 h) inhibits the proliferation of MDA-MB-231, HCT116 and HT29 cells in a dose-dependent manner with IC50s of 481 μM, >1000 μM, and 20 μM, respectively. CAIX Inhibitor S4 (3.3-33 μM; 24 h) inhibits the eGFP-MDA-MB-231 cell migration in anoxia in a concentration-dependent manner[1]. |
| In vivo | CAIX Inhibitor S4 (10 mg/kg; i.p.) inhibits the number of lung metastasis in orthotopic MDA-MB-231 mouse model without affecting primary tumor growth[1]. |
| Target activity | CA I:5600 nM (Ki), CA II:546 nM (Ki), CA XII:2 nM (Ki), CA IX:7 nM (Ki) |
| Synonyms | S4 |
| molecular weight | 335.38 |
| Molecular formula | C15H17N3O4S |
| CAS | 1330061-67-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 245 mg/mL (730.51 mM), Sonication is recommended. |
| References | 1. Gieling et al (2012) Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts. J.Med.Chem. 55 5591 |